Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1189MR)

This product GTTS-WQ1189MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1189MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6268MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ15050MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ11598MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ12063MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ11943MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ7425MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ4387MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ14404MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW